Protecting innovation in pharma is in Ireland’s interests

In Brussels, the European Commission has tabled a proposal late in its term that would weaken the incentive to produce new medicines and the jobs that come with them. The change, under discussion at meetings this week in Brussels, would mean a shortened patent protection period for new medicines, allowing for copies to be produced by generic manufacturers for export to countries outside the EU.

Categories: News Feed Tags: Tags: ,

With United States trade under a cloud, China opens to Indian pharma

China is preparing to give swift regulatory approvals to India-manufactured drugs, the head of an Indian export promotion group said, as Beijing looks for new commercial partners ahead of what could be a protracted trade war with the United States Indian firms are looking to fill gaps in Chinese demand for generic drugs, software, sugar and some varieties of rice, trade officials in New Delhi said.

Sun Pharma’s unit presses more charges against Biofrontera in patent infringement case

DUSA Pharmaceuticals, a wholly-owned subsidiary of India’s largest drugmaker Sun Pharma Thursday said it has filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against German drug maker Biofrontera and its subsidiaries in the US.

Patient group opposes Gilead’s hep C drug patents – Times of India

MUMBAI: Delhi Network of Positive People (DNP+), a patient advocacy and support group, has challenged additional patent claims by Gilead Sciences for two hepatitis C medicines before the Mumbai Patent Office. With these applications, DNP+ hopes to prevent the US pharma major from obtaining patent rights on sofosbuvir and velpatasvir, which would allow Gilead to continue charging exorbitant prices from countries across the world.

Addressing the antibiotics crisis | Letters

I read with interest your article (Antibiotics crisis made worse by shortages in supply, 1 June) on the Access to Medicine Foundation report into this topic. Its excellent report highlights an important problem. A failing supply chain along with a lack of investment in new antibiotics is already causing major health problems across the world, and this will only get worse.